Brought to you by 
Alpha Szenszor partners with Technion Israel to develop exhaled-breath lung cancer diagnostic
14 Mar 2013
Executive Summary
Alpha Szenszor Inc. (carbon nanotube sensor technology for life science applications) has chosen the Technion Israel Institute of Technology as its first partner in the development of a breath-based diagnostic for lung cancer.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Biosensors
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alpha Szenszor partners with Technion Israel to develop exhaled-breath lung cancer diagnostic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice